TY  - JOUR
AU  - Rubio-Rivas, Manuel
AU  - Mora-Luján, José M
AU  - Montero, Abelardo
AU  - Aguilar García, Josefa Andrea
AU  - Méndez Bailón, Manuel
AU  - Fernández Cruz, Ana
AU  - Oriol, Isabel
AU  - Teigell-Muñoz, Francisco-Javier
AU  - Dendariena Borque, Beatriz
AU  - De la Peña Fernández, Andrés
AU  - Fernández González, Raquel
AU  - Gil Sánchez, Ricardo
AU  - Fernández Fernández, Javier
AU  - Catalán, Marta
AU  - Cortés-Rodríguez, Begoña
AU  - Mella Pérez, Carmen
AU  - Montero Rivas, Lorena
AU  - Suárez Fuentetaja, Rebeca
AU  - Ternero Vega, Jara Eloísa
AU  - Ena, Javier
AU  - Martin-Urda Díez-Canseco, Anabel
AU  - Pérez García, Cristina
AU  - Varona, José F
AU  - Casas-Rojo, José Manuel
AU  - Millán Núñez-Cortés, Jesús
AU  - SEMI-COVID-19 Network
PY  - 2021
DO  - 10.1007/s11606-021-07146-0
UR  - http://hdl.handle.net/10668/20830
T2  - Journal of general internal medicine
AB  - The inflammatory cascade is the main cause of death in COVID-19 patients. Corticosteroids (CS) and tocilizumab (TCZ) are available to treat this escalation but which patients to administer it remains undefined. We aimed to evaluate the efficacy of...
LA  - en
KW  - COVID-19
KW  - corticosteroids
KW  - mortality
KW  - tocilizumab
KW  - treatment
KW  - Adrenal Cortex Hormones
KW  - Antibodies, Monoclonal, Humanized
KW  - Biomarkers
KW  - Humans
KW  - Inflammation
KW  - Retrospective Studies
KW  - SARS-CoV-2
KW  - COVID-19 Drug Treatment
TI  - The Use of Corticosteroids or Tocilizumab in COVID-19 Based on Inflammatory Markers.
TY  - research article
VL  - 37
ER  -